Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer
A recent study published in the journal JAMA Oncology has [...]
How long side effects last after treatment with axitinib is stopped
Axitinib is a medicine for the treatment of advanced kidney [...]
Hormonal immune-related side effects to immunotherapies
This study looked at the incidence, diagnosis and treatment of [...]
Cancer Network Patient Journey Programme
This programme of 11 webinars involves a kidney cancer patient, [...]
Side effect management for kidney cancer treatments
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
Kidney cancer patient summit on immunotherapy/TKI combinations
The following presentations from the Educated Patient® Kidney Cancer Summit [...]
Outcomes of patients who stopped immunotherapy due to immune-related side effects
Immunotherapy has changed the way advanced renal cell carcinoma (RCC) [...]
